Zusammenfassung
Hintergrund
Die symptomatische Therapie der Atemnot bei Patienten mit einer lebenslimitierenden Erkrankung ist schwierig und komplex. Ziel dieser systematischen Literaturübersicht ist die Zusammenstellung und Analyse relevanter klinischer Studien zu vier Therapieverfahren (Opioide, Benzodiazepine, Kortikosteroide, Sauerstoff) zur Linderung von Atemnot.
Material und Methoden
Die Arbeit stützt sich auf eine im Juli 2011 in Medline, Embase und der Cochrane Library durchgeführte Datenbankrecherche sowie auf Kontakt zu Experten im Feld. Eingeschlossen wurden systematische Literaturübersichten, kontrollierte und randomisiert kontrollierte Studien bei Patienten mit Atemnot aufgrund einer fortgeschrittenen Erkrankung. Die Studien wurden von zwei unabhängigen Reviewern selektiert, Daten extrahiert und bewertet. Es wurde eine narrative Synthese durchgeführt.
Ergebnisse
Aus 2559 Treffern in der Datenbanksuche wurden 5 relevante systematische Literaturübersichten und 10 randomisiert-kontrollierte Studien in die Analyse eingeschlossen. Die einzige Gruppe mit einem Wirksamkeitsnachweis sind orale und parenterale Opioide. Für Benzodiazepine zeigt sich aufgrund der aktuellen Studienlage kein signifikanter Wirksamkeitsnachweis zur Linderung der Atemnotintensität, allerdings eine Tendenz zu einem Benefit. Für Steroide konnten keine Studien identifiziert werden. Bei nichthypoxischen Tumorpatienten hat Sauerstoff keinen Benefit im Vergleich zu Raumluft, bei nichthypoxischen COPD-Patienten mit Atemnot konnte ein statistisch signifikanter Wirksamkeitsnachweis für Sauerstoff gezeigt werden.
Schlussfolgerung
Orale und parenterale Opioide zeigen einen signifikanten Wirksamkeitsnachweis und sind Mittel der 1. Wahl zur symptomatischen Therapie der Atemnot. Benzodiazepine sollten zurückhaltend eingesetzt werden. Außer bei COPD-Patienten gibt es für den Einsatz von Steroiden derzeit keine Evidenz. Nichthypoxische Tumorpatienten haben keinen Benefit von Sauerstoff gegenüber Raumluft.
Abstract
Background
The management of breathlessness in patients with life-limiting diseases is still difficult and complex. This systematic review aims to summarize and analyze clinical trials of four different treatment options (opioids, benzodiazepines, corticosteroids and oxygen) for the relief of breathlessness.
Materials and methods
A systematic review based on database searching of Medline, Embase and Cochrane Library was carried out and experts in the field were contacted. The search was conducted in July 2011. Included were systematic reviews, controlled and randomized controlled clinical trials in patients suffering from breathlessness due to advanced disease. Studies were selected, extracted and the data analyzed by two independent reviewers using narrative synthesis.
Results
The search retrieved 2,559 hits. Five systematic reviews and 10 randomized controlled trials were included. Opioids (oral and parenteral) were the only drug group with evidence for relief of breathlessness. Benzodiazepines failed to show a significant effect for the relief of breathlessness intensity but demonstrated a tendency towards benefit. No studies were identified assessing steroids. There is no additional benefit from oxygen compared to room air in non-hypoxemic cancer patients but there is a statistically significant benefit of oxygen in non-hypoxemic COPD patients.
Conclusion
Oral and parenteral opioids seem to be effective for the relief of breathlessness and should be the first choice for pharmacological treatment. Benzodiazepines should be used with reservation. There is not enough evidence for the use of steroids except for COPD patients. Non-hypoxemic cancer patients do not benefit from oxygen. The English full text version of this article will be available in SpringerLink as of November 2012 (under “Supplemental”).
Literatur
Abernethy AP, Currow DC, Frith P et al (2003) Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327:523–528
Abernethy AP, Mcdonald CF, Frith PA et al (2010) Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 376:784–793
Bausewein C, Farquhar M, Booth S et al (2007) Measurement of breathlessness in advanced disease: a systematic review. Respir Med 101:399–410
Blinderman CD, Homel P, Billings JA et al (2008) Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage 35:594–603
Booth S (2006) Improving research methodology in breathlessness: a meeting convened by MRC clinical trials unit and the Cicely Saunders Foundation. Palliat Med 20:219–220
Charles MA, Reymond L, Israel F (2008) Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 36:29–38
Clemens KE, Klaschik E (2008) Effect of hydromorphone on ventilation in palliative care patients with dyspnea. Support Care Cancer 16:93–99
Clemens KE, Klaschik E (2007) Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 33:473–481
Clemens KE, Quednau I, Klaschik E (2008) Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 11:204–216
Cranston JM, Crockett A, Currow D (2008) Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev:CD004769
Currow DC, Abernethy AP (2010) Potential opioid-sparing effect of regular benzodiazepines in dyspnea: longer duration of studies needed. J Pain Symptom Manage 40:e1–e4
Currow DC, Mcdonald C, Oaten S et al (2011) Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 42:388–399
Franzen D, Fessler J, Fischer J et al (2004) The Guideline Clearing Project COPD. Recommendations for a National Guideline. Pneumologie 58:858–862
Gaertner J, Ruberg K, Schlesiger G et al (2011) Drug interactions in palliative care – it’s more than cytochrome P450. Palliat Med (in press)
Galbraith S, Fagan P, Perkins P et al (2010) Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 39:831–838
Henoch I, Bergman B, Gustafsson M et al (2007) The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manage 34:370–379
Jennings AL, Davies AN, Higgins JP et al (2001) Opioids for the palliation of breathlessness in terminal illness. [Review] [70 refs]. Cochrane Database Syst Rev 4:CD002066
Jensen D, Alsuhail A, Viola R et al (2012) Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage 43:706–719
Johnson MJ, Mcdonagh TA, Harkness A et al (2002) Morphine for the relief of breathlessness in patients with chronic heart failure—a pilot study. Eur J Heart Fail 4:753–756
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
Mazzocato C, Buclin T, Rapin CH (1999) The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized, double-blind controlled trial. Ann Oncol 10:1511–1514
Murtagh FE, Addington-Hall JM, Higginson IJ (2007) The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 14:82–99
Navigante AH, Castro MA, Cerchietti LC (2010) Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 39:820–830
Navigante AH, Cerchietti LC, Castro MA et al (2006) Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 31:38–47
Oxberry SG, Torgerson DJ, Bland JM et al (2011) Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail 13:1006–1012
Parshall MB, Schwartzstein RM, Adams L et al (2012) An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 185:435–452
Radbruch L, Alt-Epping B, Rolke R et al (2012) Methodik und Entwicklung von Therapieempfehlungen zur Symptomkontrolle in der Palliativmedizin. Schmerz. DOI 10.1007/s00482-012-1219-4
Reddy SK, Parsons HA, Elsayem A et al (2009) Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 12:29–36
Simon ST, Higginson IJ, Booth S et al (2010) Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev:CD007354
Solano JP, Gomes B, Higginson IJ (2006) A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 31:58–69
Stege G, Heijdra YF, Van Den Elshout FJ et al (2010) Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med 104:518–524
Uronis H, Mccrory DC, Samsa G et al (2011) Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database Syst Rev CD006429
Uronis HE, Currow DC, Mccrory DC et al (2008) Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer 98:294–299
Windisch W, Walterspacher S, Siemon K et al (2010) Guidelines for non-invasive and invasive mechanical ventilation for treatment of chronic respiratory failure. Published by the German Society for Pneumology (DGP). Pneumologie 64:640–652
Interessenkonflikt
Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehungen hin: Der Erstautor ist verantwortlich für die Durchführung einer klinischen Studie (IIT) zur Wirksamkeit von Fentanyl bei Atemnot, die von TEVA GmbH finanziell unterstützt wird. Die weiteren Autoren geben keine Interessenkonflikte an.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simon, S., Köskeroglu, P. & Bausewein, C. Medikamentöse Therapie der refraktären Atemnot. Schmerz 26, 515–522 (2012). https://doi.org/10.1007/s00482-012-1228-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00482-012-1228-3
Schlüsselwörter
- Lebenslimitierende Erkrankung
- Refraktäre Atemnot
- Medikamentöse Therapie
- Literaturübersicht
- Klinische Studien